After treatment, 3D fixation and quantitative imaging analysis of CD138+ myeloma cells and healthy control lymphocytes, we found that all patients showed a response to one, two or three SINE compounds for their myeloma cells (Table 2). The gene discussed is SDC1; the disease is plasma cell myeloma.